Literature DB >> 15018835

Glutamate systems in cocaine addiction.

Peter W Kalivas1.   

Abstract

All addictive drugs facilitate dopamine transmission, and determining the role of dopamine has been the predominant focus of biomedical research in addiction for 20 years. Newer data and hypotheses have begun to shift our focus to involvement of cortex and corticofugal glutamate projections. The rationale for shifting focus to glutamate ranges from evidence showing that cortical activity is altered in addicts to data from animal models demonstrating drug-induced changes in the function of proteins that regulate pre- and postsynaptic glutamate neurotransmission. Recent studies have particularly focused on involvement of a circuit that includes glutamate projections from the prefrontal cortex to the nucleus accumbens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018835     DOI: 10.1016/j.coph.2003.11.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  124 in total

1.  fMRI response in the medial prefrontal cortex predicts cocaine but not sucrose self-administration history.

Authors:  Hanbing Lu; Svetlana Chefer; Pradeep K Kurup; Karine Guillem; D Bruce Vaupel; Thomas J Ross; Anna Moore; Yihong Yang; Laura L Peoples; Elliot A Stein
Journal:  Neuroimage       Date:  2012-06-01       Impact factor: 6.556

2.  Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.

Authors:  Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer
Journal:  Psychol Addict Behav       Date:  2014-11-03

3.  A silent synapse-based mechanism for cocaine-induced locomotor sensitization.

Authors:  Travis E Brown; Brian R Lee; Ping Mu; Deveroux Ferguson; David Dietz; Yoshinori N Ohnishi; Ying Lin; Anna Suska; Masago Ishikawa; Yanhua H Huang; Haowei Shen; Peter W Kalivas; Barbara A Sorg; R Suzanne Zukin; Eric J Nestler; Yan Dong; Oliver M Schlüter
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 4.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 5.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

6.  Effects of cocaine rewards on neural representations of cognitive demand in nonhuman primates.

Authors:  Robert E Hampson; Linda J Porrino; Ioan Opris; Terrence Stanford; Sam A Deadwyler
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

7.  Altered sensitivities to morphine and cocaine in scaffold protein tamalin knockout mice.

Authors:  Masaaki Ogawa; Tsuyoshi Miyakawa; Kenji Nakamura; Jun Kitano; Kenryo Furushima; Hiroshi Kiyonari; Rika Nakayama; Kazuki Nakao; Koki Moriyoshi; Shigetada Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-31       Impact factor: 11.205

8.  Cocaine-induced loss of white matter proteins in the adult mouse nucleus accumbens is attenuated by administration of a β-lactam antibiotic during cocaine withdrawal.

Authors:  Jane Kovalevich; Gladys Corley; William Yen; Scott M Rawls; Dianne Langford
Journal:  Am J Pathol       Date:  2012-09-29       Impact factor: 4.307

9.  Sensitizing regimens of (+/-)3, 4-methylenedioxymethamphetamine (ecstasy) elicit enduring and differential structural alterations in the brain motive circuit of the rat.

Authors:  K T Ball; C L Wellman; E Fortenberry; G V Rebec
Journal:  Neuroscience       Date:  2009-02-21       Impact factor: 3.590

10.  Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial.

Authors:  Annie Umbricht; Anthony DeFulio; Erin L Winstanley; D Andrew Tompkins; Jessica Peirce; Miriam Z Mintzer; Eric C Strain; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2014-04-16       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.